Ceera Investments LLC Decreases Stock Position in Veeva Systems Inc. (NYSE:VEEV)

Ceera Investments LLC lowered its stake in Veeva Systems Inc. (NYSE:VEEV) by 1.2% during the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 20,130 shares of the technology company’s stock after selling 235 shares during the period. Veeva Systems makes up approximately 1.5% of Ceera Investments LLC’s holdings, making the stock its 26th largest holding. Ceera Investments LLC’s holdings in Veeva Systems were worth $4,232,000 as of its most recent SEC filing.

Several other large investors have also recently modified their holdings of VEEV. MassMutual Private Wealth & Trust FSB grew its stake in shares of Veeva Systems by 72.5% in the fourth quarter. MassMutual Private Wealth & Trust FSB now owns 119 shares of the technology company’s stock worth $25,000 after purchasing an additional 50 shares during the last quarter. Centricity Wealth Management LLC bought a new stake in shares of Veeva Systems in the fourth quarter worth about $25,000. Smithfield Trust Co grew its stake in shares of Veeva Systems by 145.5% in the fourth quarter. Smithfield Trust Co now owns 135 shares of the technology company’s stock worth $27,000 after purchasing an additional 80 shares during the last quarter. True Wealth Design LLC grew its stake in shares of Veeva Systems by 3,375.0% in the third quarter. True Wealth Design LLC now owns 139 shares of the technology company’s stock worth $29,000 after purchasing an additional 135 shares during the last quarter. Finally, Avion Wealth grew its stake in shares of Veeva Systems by 635.0% in the fourth quarter. Avion Wealth now owns 147 shares of the technology company’s stock worth $30,000 after purchasing an additional 127 shares during the last quarter. Hedge funds and other institutional investors own 88.20% of the company’s stock.

Wall Street Analyst Weigh In

VEEV has been the topic of several recent analyst reports. Bank of America raised their target price on Veeva Systems from $280.00 to $290.00 and gave the stock a “neutral” rating in a research note on Friday, December 6th. Morgan Stanley lifted their price objective on Veeva Systems from $195.00 to $201.00 and gave the company an “underweight” rating in a research report on Thursday. JPMorgan Chase & Co. lifted their price objective on Veeva Systems from $208.00 to $218.00 and gave the company a “neutral” rating in a research report on Monday, December 16th. The Goldman Sachs Group cut Veeva Systems from a “buy” rating to a “sell” rating and cut their price objective for the company from $261.00 to $200.00 in a research report on Thursday, January 23rd. Finally, Truist Financial lifted their price objective on Veeva Systems from $210.00 to $217.00 and gave the company a “hold” rating in a research report on Thursday. Two research analysts have rated the stock with a sell rating, eight have given a hold rating and sixteen have issued a buy rating to the company’s stock. According to MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $255.28.

Veeva Systems Stock Up 4.6 %

Shares of NYSE VEEV opened at $247.10 on Friday. Veeva Systems Inc. has a twelve month low of $170.25 and a twelve month high of $258.93. The firm has a market cap of $40.12 billion, a P/E ratio of 61.01, a PEG ratio of 1.89 and a beta of 0.88. The company has a 50 day moving average of $224.92 and a 200 day moving average of $220.21.

Veeva Systems Company Profile

Veeva Systems Inc provides cloud-based software for the life sciences industry. It offers Veeva Commercial Cloud, a suite of software and analytics solutions, such as Veeva customer relationship management (CRM) that enable customer-facing employees at pharmaceutical and biotechnology companies; Veeva Vault PromoMats, an end-to-end content and digital asset management solution; Veeva Vault Medical that provides source of medical content across multiple channels and geographies; Veeva Crossix, an analytics platform for pharmaceutical brands; Veeva OpenData, a customer reference data solution; Veeva Link, a data application that allows link to generate real-time intelligence; and Veeva Compass includes de-identified and longitudinal patient data for the United States.